Gilead Sciences’ subsidiary Kite Pharma has acquired Interius BioTherapeutics for $350 million, gaining proprietary in vivo CAR-T cell therapy technology that enables genetic modification of immune cells directly within the patient. This acquisition marks Gilead’s entry into the emerging field of in vivo cell therapies, which aim to simplify and improve scalability compared to traditional ex vivo CAR-T treatments. The deal is part of a broader industry trend with major pharma firms investing heavily in in vivo CAR-T development to expand the applicability and accessibility of these transformative cancer therapies.